|
|
Lemaitre Vascular Inc (NASDAQ: LMAT) |
|
Price: $86.1300
$1.50 
1.772%
|
| Day's High:
| $86.13
| Week Perf:
| 5.86 %
|
| Day's Low: |
$ 83.76 |
30 Day Perf: |
1.44 % |
| Volume (M): |
37 |
52 Wk High: |
$ 109.58 |
| Volume (M$): |
$ 3,224 |
52 Wk Avg: |
$88.09 |
| Open: |
$84.47 |
52 Wk Low: |
$62.40 |
|
|
| Market Capitalization (Millions $) |
1,965 |
| Shares
Outstanding (Millions) |
23 |
| Employees |
1,150 |
| Revenues (TTM) (Millions $) |
219 |
| Net Income (TTM) (Millions $) |
44 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
7 |
Lemaitre Vascular Inc
Lemaitre Vascular Inc. is a leading provider of medical devices for the treatment of peripheral arterial disease (PAD) and other vascular disorders. The company was founded in 1983 and is headquartered in Burlington, Massachusetts.
The mission of Lemaitre Vascular is to improve patient care by providing innovative and high-quality medical devices to healthcare professionals. The company has a wide range of products that are used in the treatment of PAD, including stents, balloons, catheters, and other devices.
Lemaitre Vascular has a global presence, with offices and distribution channels in over 30 countries. The company has a highly skilled team of employees, including engineers, scientists, and healthcare professionals, who work together to develop and market new products and technologies.
In addition to its core product offerings, Lemaitre Vascular is committed to developing new and innovative solutions to address the needs of patients with vascular disorders. The company has a strong focus on research and development, and invests heavily in clinical studies and trials to ensure the efficacy and safety of its products.
Lemaitre Vascular has a reputation for innovation and excellence in the medical device industry, and has received numerous awards and accolades over the years. The company is also dedicated to corporate responsibility, and has implemented several sustainability initiatives aimed at reducing its environmental impact and promoting ethical and responsible business practices.
Overall, Lemaitre Vascular is a highly respected and successful company that has made significant contributions to the field of vascular medicine, and continues to work towards improving patient outcomes through innovative medical devices and technologies.
Company Address: 63 Second Avenue Burlington 1803 MA
Company Phone Number: 221-2266 Stock Exchange / Ticker: NASDAQ LMAT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Mon, Dec 16 2024 12:58 PM UTC
LeMaitre Vascular s Strategic Move: Convertible Senior Notes Offering and Its Potential ImplicationsOn December 16, 2024, LeMaitre Vascular, Inc. (Nasdaq: LMAT) took a significant step in its financial strategy by announcing a proposed offering of $150,000,000 in Convertible Senior Notes due 2030. This move, which is contingent upon market conditions, is primarily aimed at ...
|
| Lemaitre Vascular Inc
Investors are buzzing about the recent financial performance of Lemaitre Vascular Inc, as the company's profitability soared by 62.96% in the first quarter of 2024. With earnings per share jumping to $0.44 and revenue increasing by 11.875% to $52.67 million compared to the prior year period, the company is showing strong growth potential.
Additionally, net profits in the first quarter of 2024 spiked by 63.69% to $9.887 million, showcasing the company's ability to generate significant returns for shareholders. Lemaitre Vascular also highlighted improvements in profit margins, with net margin rising to 18.77% and operating margin increasing to 22.55%.
|
| Lemaitre Vascular Inc
LMAT had a remarkable fiscal period, with notable growth in both profit per share and revenue. Profit per share increased by 48.89% to $0.37 per share, while revenue rose by 19.825% to $49.07 million compared to the prior year period. This shows that Lemaitre Vascular Inc has outpaced its sector contemporaries in the Medical Equipment & Supplies sector, where the rest of the sector reported a revenue growth of only 7.86% during the same period.
The company's income per share also saw a positive growth of 12.75% from the preceding reporting period, from $0.33 to $0.37 per share. Revenue also grew by 4.823% from $46.82 million to $49.07 million. This indicates that the company's financial performance is strong and heading in the right direction.
|
| Lemaitre Vascular Inc
Lemaitre Vascular Inc, a medical device company, recently released its third-quarter financial report for 2023, and the results were quite impressive. The company's profit per share surged by 32% to $0.33 per share, and its revenue rose by a staggering 19.952% to $46.82 million, compared to the same period in the prior year.
However, it is worth noting that there was a slight deterioration in earnings per share compared to the previous reporting season, with a decrease of -8.33% from $0.36 per share. Revenue also decreased by -6.531% from $50.09 million. Despite this, the company's earnings in the July to September 30, 2023 fiscal time-frame increased by 37.5% to $7.502 million, compared to the same period a year ago when the company reported net earnings of $5.456 million.
|
| Product Service News
Published Fri, Nov 3 2023 8:23 PM UTC
LeMaitre Vascular, Inc. (Nasdaq:LMAT) recently announced their participation in three investor conferences set to take place in November. This news comes in the wake of their impressive financial performance in the second quarter of 2023, where the company witnessed a revenue increase of 18.95% year on year. However, this growth falls slightly below the average revenue growt...
|
| Per Share |
Current |
| Earnings (TTM) |
1.93 $ |
| Revenues (TTM) |
9.59 $
|
| Cash Flow (TTM) |
0.06 $ |
| Cash |
13.14 $
|
| Book Value |
14.78 $
|
| Dividend (TTM) |
0.64 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.93 $
|
| Revenues (TTM) |
9.59 $ |
| Cash Flow (TTM) |
0.06 $ |
| Cash |
13.14 $
|
| Book Value |
14.78 $ |
| Dividend (TTM) |
0.64 $ |
|
|
| |
| Americas |
|
 66.08 % |
of total Revenue |
| EMEA |
|
27.69 % |
of total Revenue |
| Asia Pacific |
|
7.41 % |
of total Revenue |
| UNITED STATES |
|
58.87 % |
of total Revenue |
| GERMANY |
|
7.18 % |
of total Revenue |
| CANADA |
|
6.16 % |
of total Revenue |
| UNITED KINGDOM |
|
5.23 % |
of total Revenue |
| Other Countries |
|
23.75 % |
of total Revenue |
| |
On May 2 2024 the Lemaitre Vascular Inc provided following guidance
LeMaitre Vascular Inc. (Nasdaq: LMAT), a leading provider of vascular devices, implants, and services, announced its financial results for the first quarter of 2024 on May 2nd. The company reported strong performance in the quarter, with revenues exceeding expectations and demonstrating solid growth in key product segments.
In addition to the positive financial results, LeMaitre Vascular Inc. also declared a quarterly dividend of $0.16 per share for the quarter. This dividend reflects the company's continued commitment to returning value to its shareholders and maintaining a strong financial position.
Looking ahead, LeMaitre Vascular Inc. provided guidance for the remainder of 2024, indicating ...
|
|
|
3.77% 